Search results for "Germany"

showing 10 items of 1172 documents

Prophylactic Thyroidectomy in 75 Children and Adolescents with Hereditary Medullary Thyroid Carcinoma: German and Austrian Experience

1998

When mutations of the RETproto-oncogene were found in 1993 to account for hereditary medullary thyroid carcinoma (MTC), surgeons obtained the opportunity to operate on patients prophylactically (i. e., at a clinically asymptomatic stage). Whether this approach is justified, and, if so, when and to which extent surgery should be performed remained to be clarified. A questionnaire was sent to all surgical departments in Germany and Austria. All of the patients who fulfilled the following criteria were enrolled: (1) preoperatively proved RET mutation; (2) age/= 20 years, (3) clinically asymptomatic thyroid C cell disease; and (4) TNM classification pT0-1/pNX/pN0-1/M0. Seventy-five patients wer…

AdultCalcitoninMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAsymptomaticThyroid carcinomaNeoplastic Syndromes HereditaryGermanymedicineCarcinomaHumansChildLymph nodebusiness.industryThyroidThyroidectomymedicine.diseaseSurgerymedicine.anatomical_structureHypoparathyroidismCalcitoninAustriaCarcinoma MedullaryChild PreschoolThyroidectomyFemaleSurgerymedicine.symptombusinessWorld Journal of Surgery
researchProduct

Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group

2015

Purpose To determine, in the setting of advanced-stage of Hodgkin lymphoma (HL), whether relapses occur in the irradiated planning target volume and whether the definition of local radiation therapy (RT) used by the German Hodgkin Study Group (GHSG) is adequate, because there is no harmonization of field and volume definitions among the large cooperative groups in the treatment of advanced-stage HL. Methods and Materials All patients with residual disease of ≥2.5 cm after multiagent chemotherapy (CTX) were evaluated using additional positron emission tomography (PET), and those with a PET-positive result were irradiated with 30 Gy to the site of residual disease. We re-evaluated all sites o…

AdultCancer ResearchNeoplasm Residualmedicine.medical_treatmentPlanning target volumeIrradiated VolumeBleomycinFluorodeoxyglucose F18RecurrenceGermanyAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineCooperative groupRadiology Nuclear Medicine and imagingRadiation treatment planningCyclophosphamideEtoposideChemotherapyRadiationmedicine.diagnostic_testbusiness.industryRadiotherapy Planning Computer-AssistedRadiotherapy DosageMiddle AgedCombined Modality TherapyHodgkin DiseaseRadiation therapyOncologyDoxorubicinVincristinePositron emission tomographyPositron-Emission TomographyProcarbazinePrednisoneHodgkin lymphomaRadiopharmaceuticalsbusinessNuclear medicineInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage.

2012

Population-based studies on ovarian cancer providing survival estimates by age, histology, laterality, and stage have been sparse. We aimed to derive the most up-to-date and detailed survival estimates for ovarian cancer patients in Germany. We used a pooled German national dataset including data from 11 cancer registries covering 33 million populations. A total of 21 651 patients diagnosed with ovarian cancer in 1997-2006 were included. Period analysis was carried out to calculate the 5-year relative survival (RS) for the years 2002-2006. Trends in survival between 2002 and 2006 were examined using model-based period analysis. Age adjustment was performed using five age groups (15-44, 45-5…

AdultCancer Researchmedicine.medical_specialtyAdolescentDatabases FactualEpidemiologyPopulationAge adjustmentYoung AdultGermanymedicineCarcinomaHumansYoung adulteducationAgedDemographyNeoplasm StagingGynecologyOvarian Neoplasmseducation.field_of_studyRelative survivalbusiness.industryNot Otherwise SpecifiedPublic Health Environmental and Occupational HealthAge FactorsCancerMiddle Agedmedicine.diseaseSurvival RateOncologyFemaleOvarian cancerbusinessEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

2021

Abstract Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients and methods GAIN-2 was an open-label, randomised, multicentre phase III trial. Two thousand eight hundred and eighty seven patients were randomised 1:1 between three courses each of idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC) versus four cycles of leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by four cycles of tailored and dose-dense docetaxel (dtD) (dtEC-dtD…

AdultCancer Researchmedicine.medical_specialtyTime FactorsAdolescentPaclitaxelCyclophosphamideDose-dense chemotherapymedicine.medical_treatmentBreast NeoplasmsDocetaxelRisk AssessmentDisease-Free SurvivalYoung AdultRisk FactorsAlbuminsGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAdverse effectCyclophosphamideAgedEpirubicinChemotherapybusiness.industryCarcinoma Ductal BreastCancerMiddle AgedInterim analysismedicine.diseaseNeoadjuvant TherapyCarcinoma LobularCarcinoma Intraductal NoninfiltratingOncologyDocetaxelChemotherapy AdjuvantFemalebusinessmedicine.drugEpirubicinEuropean Journal of Cancer
researchProduct

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

2018

Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited.We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions.Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21.4% (n = 328) had triple-negative and 30.8% (n = 471) had hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The proportion of patients with HER2-positive BMs decreased comparing the years 2000-2009 with 2010-2015 (51%-44%), whereas the percenta…

AdultCancer Researchmedicine.medical_specialtyTime FactorsReceptor ErbB-2Posterior fossaAge at diagnosisBreast NeoplasmsTriple Negative Breast NeoplasmsYoung Adult03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifeRisk FactorsGermanyInternal medicineBiomarkers TumormedicineHumansRegistriesskin and connective tissue diseasesAgedRetrospective StudiesAged 80 and overBrain Neoplasmsbusiness.industryMiddle Agedmedicine.diseaseTreatment OutcomeOncologyHormone receptor030220 oncology & carcinogenesisCohortLife expectancyFemalePrimary breast cancerbusiness030217 neurology & neurosurgeryEuropean Journal of Cancer
researchProduct

Lack of association of a functional catechol-O-methyltransferase gene polymorphism with risk of tobacco smoking: results from a multicenter case-cont…

2013

Background The catechol-O-methyltransferase (COMT) modulates dopaminergic neurotransmission in the prefrontal cortex as well as in the mesolimbic reward system. Since the reward system mediates addictive behavior, the COMT gene is a strong candidate gene regarding the pathophysiology of tobacco dependence and smoking behavior. Because of rather conflicting results in previous studies, the purpose of the present study was to test for association between a functional genetic variant in the COMT gene (single nucleotide polymorphism [SNP] rs4680) and tobacco smoking behavior. Methods In a population-based case-control multicenter study designed for tobacco addiction research, a total of 551 cur…

AdultCandidate genemedia_common.quotation_subjectPopulationEuropean Continental Ancestry Groupgenetics [Catechol O-Methyltransferase]Single-nucleotide polymorphism610 Medicine & healthCatechol O-MethyltransferasePolymorphism Single NucleotideWhite PeopleGermanymental disordersSNPMedicineHumanseducationmedia_commonGeneticseducation.field_of_studyCatechol-O-methyl transferasebusiness.industryAddictionSmokingPublic Health Environmental and Occupational Healthgenetics [Smoking]Tobacco Use Disorder2739 Public Health Environmental and Occupational HealthMiddle Agedmedicine.diseaseCase-Control Studies10054 Clinic for Psychiatry Psychotherapy and Psychosomaticsddc:640genetics [Tobacco Use Disorder]businessAddictive behaviorrs4680
researchProduct

Pregnancy in primary sclerosing cholangitis

2011

Background There is a paucity of data on fertility or pregnancy in patients with primary sclerosing cholangitis (PSC). Objective To assess fertility in PSC by comparing the number of children in a large cohort of PSC patients to healthy controls and to investigate the outcome of pregnancy, as well as the influence of pregnancy on the disease course. Design Case series. Setting Germany. Participants 229 PSC patients and 569 healthy controls were evaluated for the number of children. 17 patients with PSC and at least one pregnancy, or who received a diagnosis of PSC within 6 months after delivery, were included in the more detailed analysis. Main outcome measures Number of children per patien…

AdultCholagogues and Cholereticsmedicine.medical_specialtyTime FactorsAdolescentmedia_common.quotation_subjectCholangitis SclerosingFertilityAutoimmune hepatitisPrimary sclerosing cholangitisYoung AdultPregnancyRisk FactorsGermanyAzathioprinemedicineHumansYoung adultmedia_commonPregnancyFetusObstetricsbusiness.industryIncidenceIncidence (epidemiology)Ursodeoxycholic Aciddigestive oral and skin physiologyInfant NewbornPregnancy OutcomeGastroenterologymedicine.diseasedigestive system diseasesPregnancy ComplicationsImmunologyGestationFemalebusinessImmunosuppressive AgentsFollow-Up StudiesGut
researchProduct

Chromated metal products may be hazardous to patients with chromate allergy.

2009

Background:  Hidden allergen exposure may contribute to persistence and relapse of chromate dermatitis. According to case reports, chromated metal products, such as screws, fittings, etc., may be relevant allergen sources for patients sensitized to chromate. Objectives:  To examine concomitant patch test reactivity to potassium dichromate 0.5% petrolatum (pet.) and three different types of chromated metal rings. Patients/Methods:  Patients with proven or suspected chromate allergy were patch tested with potassium dichromate 0.5% pet. and three different types of chromated metal rings (yellow, olive, and black). Hexavalent chromium Cr(VI) release from the patch tested rings was chemically an…

AdultChromiumMaleAllergyDermatologyMetal030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineChromium CompoundsGermanymedicineImmunology and AllergyHumansIn patientHexavalent chromium030223 otorhinolaryngologyPotassium dichromateChromate conversion coatingMetallurgyPatch testAllergensMiddle AgedPatch Testsmedicine.disease3. Good healthchemistryvisual_artDermatitis Allergic Contactvisual_art.visual_art_mediumFemalePotassium DichromateContact dermatitisNuclear chemistryContact dermatitis
researchProduct

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

2010

The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 μg/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/μL. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 …

AdultCompassionate Use TrialsMalemedicine.medical_specialtyBenzylaminesAdolescentStem cell mobilizationmedicine.medical_treatmentCyclamsPoor mobilizersGermanYoung AdultHeterocyclic CompoundsGermanyGranulocyte Colony-Stimulating FactormedicineHumansIntensive care medicineChildAgedTransplantationChemotherapybusiness.industryPlerixaforLymphoma Non-HodgkinHematopoietic Stem Cell TransplantationCompassionate UseHematologyMiddle AgedCombined Modality TherapyHodgkin Diseasehumanitieslanguage.human_languageHematopoietic Stem Cell MobilizationTreatment OutcomeChild PreschoollanguageBlood Component RemovalFemalebusinessMultiple Myelomamedicine.drugBone marrow transplantation
researchProduct

Use of complementary and alternative medicine: A multicenter cross-sectional study in 1089 melanoma patients.

2016

Abstract Background About half of patients with cancer use complementary and alternative medicine (CAM). So far, data on melanoma patients are missing. Objective The aim of our study was to evaluate the prevalence and predictors for the use of CAM in this patient group. Methods All patients with melanoma being attended at one of 7 skin cancer centres in Germany between March 2012 and March 2013 were invited to take part in a survey using a structured questionnaire on CAM. The physicians filled in a second part on the diagnosis, state and former and current therapy. Results Nearly half of the 1089 participants (41.0%) used CAM and half of those using CAM (56.8%) marked that this made them fe…

AdultComplementary TherapiesCancer Researchmedicine.medical_specialtyHealth Knowledge Attitudes Practiceanimal structuresCross-sectional studyAlternative medicine03 medical and health sciences0302 clinical medicineGermanymedicineHumans030212 general & internal medicinePatient groupMelanomaAgedAged 80 and overbusiness.industryPrint mediaMelanomaCancerMiddle AgedPatient Acceptance of Health Caremedicine.diseaseCross-Sectional StudiesLogistic ModelsOncology030220 oncology & carcinogenesisFamily medicineFemaleSkin cancerbusinessPsychosocialEuropean journal of cancer (Oxford, England : 1990)
researchProduct